Novartis Venture Fund has led the series A round for drug company Neurovance to develop their non-addictive ADHD combating drug.
Novartis Venture Fund. the $750m corporate venturing division of pharmaceutical firm Novartis, has led a $7m Series A round for U.S-based startup Neurovance, a spin off of Euthymics Bioscience.
Neurovance is developing a new drug, EB-1020, for adult attention deficit hyperactivity disorder. Venture Investors, H&Q Healthcare Investors and H&Q Life Sciences Investors, GBS Venture Partners, State of Wisconsin Investment Board and Timothy Barberich also participated in the A round. The round follows a $478,000 round closed earlier this year by…
